• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Heart Tumor Companies

    ID: MRFR/HC/3629-CR
    137 Pages
    Kinjoll Dey
    September 2022

    There were several companies involved in research and development focused on the diagnosis and treatment of heart tumors, which can include primary cardiac tumors and metastatic tumors that affect the heart.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Heart Tumor Market Research Report—Global Forecast till 2032 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Heart Tumor Market

    Heart Tumor Key CompaniesLatest heart tumor Companies Update



    • May 2023: Sotagliflozin, developed by Lexicon Pharmaceuticals, has been given the green light to treat a wide variety of left ventricular ejection fraction in both diabetic and non-diabetic patients. For the first time, both preserved and lowered ejection fraction HF may be treated with this drug since it is a dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor. Lexicon Pharmaceuticals was successful in its pursuit of a wide HF label that would encompass patients with and without diabetes, and they were rewarded with approval. Although SGLT2 inhibitors are well-established treatments for heart failure (HF), chronic kidney disease (CKD), and type 2 diabetes (T2D), the upcoming SGLT1-blocking therapy is novel.




    • March 2023: Royal Philips, a world leader in healthcare technology, introduced Philips Virtual Care Management, a suite of adaptable solutions and services designed to help healthcare organizations improve patient engagement and satisfaction through remote, individualized care. Better treatment of chronic diseases and fewer trips to the emergency room are two benefits of Philips Virtual Care treatment that can relieve strain on hospital staff. The new approach has been shown to improve workflow efficiency, patient engagement, and health outcomes while reducing the cost of treatment.




    • April 2023: Moderna announced their goal of releasing a series of cancer, heart disease, and other once incurable illness vaccines by 2030. With the success of its mRNA Covid vaccine, Moderna has successfully navigated the post-pandemic boom. Using its messenger RNA technology, the Cambridge, Massachusetts firm has become well-known for training human cells to generate a protein that triggers an immune response to a specific illness. Since the beginning of the Covid pandemic, breakthroughs in messenger RNA (mRNA) technology have ushered in a golden period for novel injections.List of heart tumor Media Key companies in the market

    • Koninklijke Philips N.V (The Netherlands)

    • FUJIFILM Corporation (Japan)

    • GE Healthcare (US)

    • Siemens (Germany)

    • Amneal Pharmaceuticals llc (US)

    • Shimadzu Corporation (Japan)

    • TomTec Imaging Systems GmbH (Germany)

    • Toshiba Corporation (Japan)

    • Boston Scientific Corporation (US)

    • Terumo cardiovascular systems corporation (US)